European Pharmaceutical Review

European Pharmaceutical Review is a top-tier publication focused on advancements in drug discovery and manufacturing. The sixth issue of 2015 is part of a bi-monthly series that provides in-depth technical insights and business contributions from premier pharmaceutical companies and academic organizations globally. Each issue includes a range of engaging content, such as interviews, updates, and profiles, making it a valuable resource for industry professionals.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#624754

India

#167057

Science and Education/Biology

#363

Traffic sources

Monthly visitors

Articles

GSK to expand hepatology pipeline with potential best-in-class drug

2 days ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 14 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The unique mechanism of action of efimosfermin supports its potential as a new standard-of-care in liver disease. GSK has agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for up to $2 billion. The Phase III-ready injectable drug has best-in-class potential to treat and prevent progression of steatotic liver disease (SLD).
Novel cancer treatment approach significantly enhances survival

3 days ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 13 May 2025 | Catherine Eckford (European Pharmaceutical Review) | With its detailed safety data for chemotherapy and olaparib to treat early-stage breast cancer, the trial findings could lead to improved patient outcomes. New research has proposed a novel approach for treating early-stage breast cancer with inherited BRCA1 and BRCA2 gene mutations. One hundred percent of patients survived three-years post-surgery, indicating the most effective treatment to date for this indication.
World-first approval supports AstraZeneca’s sustainability goals

4 days ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 12 May 2025 | Catherine Eckford (European Pharmaceutical Review) | Approval of the novel tool marks progress for both respiratory disease patients in the UK and reducing the global environmental impact of inhaled medicines. The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted approval of the low-carbon version of the chronic obstructive pulmonary disorder (COPD) inhaler Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF).
Innovative CAR T therapy could deliver in broader therapy settings

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 9 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The novel cell therapy utilises a shortened manufacturing process compared to standard production timelines, offering potential for enhanced therapeutic capability. A next-generation CAR T cell therapy has shown promise for treatment-resistant B-cell lymphoma, new research shows.
Tackling EU supply chain challenges while boosting innovation

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 8 May 2025 | Catherine Eckford (European Pharmaceutical Review) | Medicines for Europe calls for continued progress of pharmaceutical reforms such as the Critical Medicines Act, to support production of essential medicines in the region. As EU Health Ministries approach the final stages of negotiations on the future of Europe’s pharmaceutical rules, Medicines for Europe has called for key actions to ensure medicine supply is protected in the region.
UK-India trade deal insufficient for life sciences, says industry body

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 7 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The multi-billion-pound deal provides a boost to the UK’s economy, however it lacks provision to aid the country’s growth ambitions, states the ABPI. The UK and India have agreed a major trade deal, however it does not provide sufficient support the UK pharmaceutical industry, according to the Association of the British Pharmaceutical Industry (ABPI).
A EU regulatory framework for enhanced pharma competitiveness

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 6 May 2025 | Catherine Eckford (European Pharmaceutical Review) | Despite its potential to become a more attractive destination for drug developers, new research insists the EU market makes improvements such as faster regulatory approvals and closer collaboration. New research reports that financial barriers, alongside regulatory restrictions and other factors, are making pharmaceutical companies choose the US over the EU market.
New J&J data signals progress in UC treatment landscape

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 5 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The biologic delivered sustained remission in adults with the inflammatory bowel disease (IBD) over the two-year study, results show. New clinical findings show that Johnson & Johnson’s monoclonal antibody Tremfya ® (guselkumab) enabled sustained clinical and endoscopic efficacy for ulcerative colitis patients at two years.
Key trends and technologies in drug delivery for 2025 and beyond

1 week ago | europeanpharmaceuticalreview.com | Ian Betteridge

Posted: 5 May 2025 | Ian Betteridge (RPL) | This article delves into the key trends shaping drug delivery amid a surge of innovation, including advanced delivery systems and sustainability, and offers an outlook for the future of the sector. Drug delivery technology is undergoing rapid innovation worldwide. Pharmaceutical manufacturers are adopting advanced delivery platforms to improve drug efficacy and patient compliance, while scaling production for global distribution.
FDA approves first-of-a-kind gene therapy for DEB

2 weeks ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 2 May 2025 | Catherine Eckford (European Pharmaceutical Review) | With clinical data showing the gene therapy can address large and challenging chronic wounds, the FDA’s decision will help improve quality of life for dystrophic epidermolysis bullosa (DEB) patients. The US Food and Drug Administration (FDA) has approved Zevaskyn ™ (prademagene zamikeracel) as the first autologous cell-based gene therapy for treating recessive dystrophic epidermolysis bullosa (RDEB) wounds.